{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:10:12Z","timestamp":1767611412323,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s13365-020-00899-0","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T14:05:21Z","timestamp":1599746721000},"page":"961-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-4536","authenticated-orcid":false,"given":"Alex","family":"Holmes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Wellings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Rowlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"2","key":"899_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/10428194.2018.1474523","volume":"60","author":"D Adrianzen Herrera","year":"2019","unstructured":"Adrianzen Herrera D, Ayyappan S, Jasra S, Kornblum N, Derman O, Shastri A, Mantzaris I, Verma A, Braunschweig I, Janakiram M (2019) Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant \u2013 a case series. Leuk Lymphoma 60(2):395","journal-title":"Leuk Lymphoma"},{"key":"899_CR2","doi-asserted-by":"crossref","unstructured":"Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. (2019) Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 6(6)","DOI":"10.1212\/NXI.0000000000000618"},{"issue":"8","key":"899_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"K Carson","year":"2009","unstructured":"Carson K, Focosi D, Major E, Petrini M, Richey E, West D, Bennett C (2009) Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10(8):816\u2013824","journal-title":"Lancet Oncol"},{"key":"899_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"3800","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M et al (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 3800:1597\u20131605","journal-title":"N Engl J Med"},{"issue":"6","key":"899_CR5","doi-asserted-by":"publisher","first-page":"e20967","DOI":"10.1371\/journal.pone.0020967","volume":"6","author":"J Gasnault","year":"2011","unstructured":"Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y, for the ANRS 125 Trial Team (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6(6):e20967. https:\/\/doi.org\/10.1371\/journal.pone.0020967","journal-title":"PLoS One"},{"issue":"6","key":"899_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic D, Patera A, Nyberg F, Gerber M, Liu M (2015) Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8(6):255","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"899_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"C Tan","year":"2010","unstructured":"Tan C, Koralnik I (2010) Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol 9(4):425\u2013437","journal-title":"Lancet Neurol"},{"issue":"2","key":"899_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12185-012-1118-6","volume":"96","author":"S Warsch","year":"2012","unstructured":"Warsch S, Hosein PJ, Morris MI, Teomete U, Benveniste R, Chapman JR, Lossos IS (2012) Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab. Int J Hematol 96(2):274\u2013278","journal-title":"Int J Hematol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-020-00899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-020-00899-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-020-00899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T01:12:40Z","timestamp":1631236360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-020-00899-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s13365-020-00899-0","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"type":"print","value":"1355-0284"},{"type":"electronic","value":"1538-2443"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}